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Abstract
Background: The cAMP-dependent protein kinase A (PKA) plays a pivotal role in virtually all cells, there being a 
multitude of important target molecules that are substrates for PKA in cell signaling. The spatial-temporal dynamics of 
PKA activation in living cells has been made accessible by the development of clever biosensors that yield a FRET signal 
in response to the phosphorylation by PKA. AKAR2 is genetically encoded fluorescent probe that acts as a biosensor for 
PKA activation. AKAP12 is a scaffold that docks PKA, G-protein-coupled receptors, cell membrane negatively-charged 
phospholipids, and catalyzes receptor resensitization and recycling. In the current work, the AKAR2 biosensor was 
fused to the N-terminus of AKAP12 to evaluate its ability to function and report on dynamic phosphorylation of the 
AKAP12 scaffold.
Results: AKAR2-AKAP12 can be expressed in mammalian cells, is fully functional, and reveals the spatial-temporal 
activation of AKAP12 undergoing phosphorylation by PKA in response to beta-adrenergic activation in human 
epidermoid carcinoma A431 cells.
Conclusion: The dynamic phosphorylation of AKAP12 "biosensed" by AKAR2-AKAP12 reveals the scaffold in association 
with the cell membrane, undergoing rapid phosphorylation by PKA. The perinuclear, cytoplasmic accumulation of 
phosphorylated scaffold reflects the phosphorylated, PKA-activated form of AKAP12, which catalyzes the 
resensitization and recycling of desensitized, internalized G-protein-coupled receptors.
Background
The discovery of a class of scaffold proteins that harbor a
binding site for the regulatory subunits (i.e., RI/RII) of
cyclic AMP-dependent protein kinase A (PKA, A-kinase)
was seminal in our understanding of the roles of these A-
Kinase Anchoring Proteins (AKAPs), in many facets of
cellular signaling [1]. AKAPs not only dock PKA, but also
can act as molecular "tool boxes" that capable of docking
protein kinases other than PKA (including protein kinase
C, PKC, and the Src-family tyrosine kinases), phosphop-
rotein phosphatases (such as protein phosphatase-2B),
and adaptor molecules [2]. AKAPs participate dynami-
cally in such large, macromolecular signaling complexes
that can include not only protein kinases and phosphop-
rotein phosphatases, but also phosphodiesterases (PDE),
adaptor molecules (like Grb2), ion channels, and mem-
bers of the superfamily of G protein-coupled receptors
(GPCR) [3]. Two AKAPs, AKAP12 (as known as
AKAP250, gravin, and SSECKS) and AKAP5 associate
with the beta-adrenergic receptors and have been the
focus of intense research [2-6]. Human epidermoid carci-
noma A431 cells express AKAP12 and a full complement
of the prototypic GPCR, the beta2-adrenergic receptor
[7-10]. A431 cells have been well-characterized with
respect to PKA-based cell signaling [7-10] and were
adopted for the current studies.
One of the major obstacles in understanding the pre-
cise functions of signaling molecules like AKAP scaffolds
is the inability to ascertain the spatial-temporal dynamics
of the molecules during activation of a signaling pathway
[11]. Most approaches (e.g., immunohistochemical and
imaging with autofluorescent-tagged molecules) provide
signals from the entire cellular complement of a specific
molecule, when what truly is sought is study of only the
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subset of these molecules that are actively involved in the
signaling, which may represent a vanishing small percent-
age. The advent of powerful "biosensors" that can report
on changes in function as a result of activation of a kinase
(e.g., AKAR/AKAR2 reporting phosphorylation events
catalyzed by PKA) provide a novel avenue with which to
study of the spatial-temporal signaling of PKA [12].
AKAR2, employed in this study, is a biosensor for PKA
phosphorylation that includes the cyan fluorescent pro-
tein (CFP), a consensus substrate sequence for PKA-cata-
lyzed phosphorylation, a phosphoamino acid-binding
sequence of the Forkhead Homology domain, and citrine,
a less pH-sensitive variant of enhanced yellow fluorescent
protein (YFP) [11,12]. Phosphorylation of the PKA con-
sensus sequence of AKAR2 induces tight binding of the
phosphoamino acid-binding domain provoking proxim-
ity of CFP and YFP, generating fluorescence resonance
energy transfer (FRET) [11,12]. We have sought a hybrid
approach that combines the power of the AKAR2 biosen-
sor with a desire to measure not all of the events cata-
lyzed by PKA, but only those confined intentionally to a
single PKA substrate AKAP12 [13-15]. PKA phosphory-
lation of AKAP12 is central to the function of this scaf-
fold, essential to the ability of AKAP12 to resensitize and
recycle GPCRs in cells following the activation of adenyl
cyclase, a rise in intracellular cyclic AMP, and the activa-
tion of PKA [14]. PKA-catalyzed phosphorylation also
regulates other AKAP scaffolds that bind GPCRs
[1,5,6,15]. Herein, we seek to probe the dynamic, spatial-
temporal character of AKAP12 by creating a fusion pro-
tein of the biosensor AKAR2 with the AKAP12. We char-
acterize a fusion construct that retains all the functional
capability of the AKAP12, but can, by virtue of its AKAR2
moiety, report as a biosensor on the phosphorylation of
AKAR2-AKAP12 in living cells.
Results and Discussion
The biosensor moiety for protein kinase A-dependent
phosphorylation, AKAR2 [12], was fused to the N-termi-
nus of AKAP12 in a simple two-step strategy (Fig. 1A).
The positively-charged domains (PCDs) are localized in
the N-terminus of AKAP12 [13]. The addition of the
AKAR2 moiety to the N-terminus necessarily removes
the N-myristoylation of the native protein. Earlier it was
shown that in the presence of three PCDs, the loss of the
N-myristoylation site does not alter the ability of
AKAP12 to function [13]. Thereceptor-binding domain
(RBD) for GPCRs is located close to the mid-point of
AKAP12 [14] and the binding site for the RII subunit of
protein kinase A is located in the C-terminal region of the
molecule (Fig. 1B) [1-3]. We investigated the expression
of t he AKAR2 moiety alone, as a con trol, by transien t
transfection in human epidermoid carcinoma A431 cells
(Fig. 2A). The A431 cells were imaged at 473-495 nm for
CFP and 527-591 for YFP (in this case, the citrine vari-
ant). Excepting the nucleus, the distribution of AKAR2
expressed in A431 cells was uniform throughout cells, as
made clear by the fluorescent signals from the CFP and
YFP moieties of the AKAR2 molecule. Using the same
approach to highlight the nucleus by DAPI staining of live
cells, the distribution of AKAR2 throughout the cell,
excluding the nucleus, can be highlighted in the "merge"
panel (Fig. 2B).
The AKAR2-AKAP biosensor was constructed in
pcDNA3 expression vector and A431 cells were tran-
siently transfected (Fig. 3A). Expression of exogenous
AKAP12, the AKAR2 biosensor itself, or the complete
AKAR2-AKAP12 fusion biosensor protein was examined
in whole-cell lysates of A431 cells transfected with one of
the three plasmids. The lysates were subjected to SDS-
PAGE, the resolved proteins transferred to blots, and the
blots subjected to staining with primary antibodies
against either AKAP12 or against the YFP moiety. The
immunoblots reveal the expression of AKAR2 (Mr = 80
kDa), of AKAP12 itself (Mr  = 250 kDa), and of the
AKAR2-AKAP12 fusion biosensor (Mr ~300 kDa). It was
important to determine if the fusion protein retained bio-
logical function. AKAP12 plays an essential role in the
resensitization of beta2-adrenergic receptors that have
undergone agonist-induced desensitization [1-3]. Treat-
ing cells with the beta-adrenergic agonist isoproterenol
for 30 min ultimately desensitizes the treated cells, i.e.,
sharply attenuates the accumulation of intracellular cyclic
AMP in response to a second stimulation with beta-
adrenergic agonist (Fig. 3A, bottom panel). A wash-out of
agonist followed by a 60-min recovery period (W60)
leads to full functional recovery in native A431 cells, but
not in cells treated with morpholinos antisense to the 5'-
untranslated region of AKAP12 (KD AKAP12), i.e., mor-
pholinos designed to suppress expression of endogenous
AKAP12 only [13]. Morpholinos antisense for AKAP12
are used routinely to suppress the endogenous AKAP12;
typically, the reduction is more than 90% [13, and data
not shown]. Expression of the AKAR2-AKAP12 fusion
biosensor restores the ability of the cells to fully recover
from desensitization, rescuing the ability of the beta2-
adrenergic receptors of AKAP12-deficient cells to func-
tion. Thus, a fusion protein of AKAR2 N-terminal to
AKAP12 is readily expressed and displays function.
In the absence of any stimulation with a beta-adrener-
gic agonist, A431 cells expressing AKAR2-AKAP12 dis-
play a pattern of distribution very similar to that observed
earlier for eGFP-tagged AKAP12 in intact cells [13] and
much earlier for immunohistochemical staining of
AKAP12 in fixed cells [15]. By imaging the fluorochrome
reporters, AKAR2-AKAP12 can be localized in associa-
tion with the cell membrane (white arrows) as well as inTao et al. Journal of Molecular Signaling 2010, 5:3
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Figure 1 Strategy for construction of plasmid encoding a targeting biosensor, AKAR2-AKAP12. Panel A, AKAR2 (a generous gift of the labora-
tory of Dr. Roger Tsien (UCSD) was engineered to the N-terminal of AKAP12, in two steps. The AKAP12 N-terminal half of the sequence (nucleotides 
1-2180) was inserted as a Kpn1-BamH1 fragment in to the AKAR2 pcDNA3 hygro plasmid (pAKAR2-AKAP12'), as detailed in the Methods section. The 
C-terminal remainder of the AKAP12 molecule (nucleotides 2181-5346, AKAP12") was inserted as a BamH1-Not1 fragment into the pAKAR2-AKAP12' 
plasmid to generate the final construct, AKAR2-AKAP12. The AKAR2 moiety is composed of an N-terminal CFP, the Forkhead phosphoamino acid-
binding domain (blue oval), docking site and substrate domain (red oval) with specificity for PKA-catalyzed phosphorylation, and a C-terminal YFP 
(citrine variant) which is fused to the N-terminus of the AKAP scaffold protein (i.e., the "targeting" moiety for the biosensor), AKAP12. Panel B, the dock-
ing of the kinase and phosphorylating the substrate site lead to a strong interaction with the Forkhead phosphoaminoacid-binding domain. This 
phosphate group-FHA domain binding brings the CFP and YFP moieties into close proximity, enabling FRET signaling. Phosphoprotein phosphatase 
hydrolyzes the phosphophate group and relaxes the interaction between CFP and YFP, attenuating the capacity for FRET.
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large, punctiform clusters found in the perinuclear com-
partment of the cytosol (red arrows, Fig 3B). The
enhanced localization of the scaffold biosensor at the cell
membrane reflects the presence of three PCDs in the N-
terminal domain of AKAP12 [13]. Both AKAP5 and
AKAP12 share the presence of three PCDs and both scaf-
folds are found at higher relative concentrations in close
proximity to the negatively-charged cell membrane [16].
When the AKAR2-AKAP12 cells are challenged with
beta-adrenergic agonist, changes in image fluorescent
density show a rapid, sustained decrease in the signal
recorded from the CFP and a corresponding increase in
the signal recorded for the YFP (citrine, Fig. 4), i.e., a
FRET signal [11,12]. Signals recorded in the area indi-
cated demonstrate that the biosensor-AKAP has been
Figure 2 Imaging of AKAR2 expressed in human epidermoid car-
cinoma A431 cells. Panel A, images of AKAR2 biosensor when ex-
pressed in A431 cells. The fluorescence images were recorded at 473-
495 nm for CFP, and, 527-591 nm for YFP (citrine). Panel B, AKAR2-based 
fluorescence images were recorded at 473-495 nm for CFP and 527-
591 nm for YFP (citrine), in A431 cells in which the nuclei were stained 
with DAPI. The DAPI recordings were performed at 435-485 nm. The 
images shown are representative of a large array of images collected 
for this purpose.
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Figure 3 Expression of AKAR2-AKAP12 fusion protein in A431 
cells: Mr, function, and imaging. A431 cells were transfected with an 
expression vector plasmid harboring one of the following cDNAs: 
AKAR2; AKAP12; and AKAR2-AKAP12. Panel A (top), the expression of 
AKAR2, AKAP12, and AKAR2-AKAP12 was examined. The stained im-
munoblots and the approximate Mr of each resolved band is indicated. 
Panel A (bottom), A431 cells were challenged with β-agonist (isoprot-
erenol, 10 μm) for 5 min and the intracellular cAMP (pmol/105 cells) 
represents the normal response of naïve A431 cells (at time = "0"). 
Upon a 30 min challenge with isoproterenol, cells became desensi-
tized to a second, subsequent challenge with the β-agonist (30). The 
agonist was then washed out and the cells were allowed to recover. 
The "resensitization" was measured in cells at 60 min following the 
washout (W60). This activation, desensitization, wash out and recovery 
were performed on A431 cells alone (Control), on AKAP12-deficient 
cells (i.e., KD AKAP12), and on AKAP12-deficient cells transiently ex-
pressing AKAR2-AKPA12. The results, displayed as mean values ± S.E., 
are of at least three separate experiments. Panel B, imaging of cellular 
distribution of AKAR2-AKAP12 in A431 cells. The fluorescence images 
were recorded at 473-495 nm for CFP and 527-591 nm for YFP. Nuclei 
stained with DAPI were recorded at 435-485 nm. The images shown 
are representative of a large array of images collected for this purpose.
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phosphorylated and that this phosphorylation yields a
FRET signal from the "activated" AKAP. Thus, PKA-cata-
lyzed phosphorylation of AKAP12, which is essential to
its activation and function [14], yields a FRET signal from
this biosensor. This is the first such image of an AKAP
"biosensed" and recorded in the activated state, phospho-
rylated in response to the cellular stimulation with beta-
adrenergic agonist.
In order to probe the initial conclusion that the biosen-
sor-AKAP12 was reporting the phosphorylated, "active"
state necessary for its function in signaling, we employed
several well-known tests as controls. If the FRET signal
(increased YFP signal) reflected PKA-catalyzed phospho-
rylation of the AKAP12 biosensor, then we might expect
that inhibition of PKA itself would impact the FRET sig-
nal. We treated cells with beta-adrenergic agonist for 30
min to stimulate the FRET signal and then treated the
cells with the PKA inhibitor KT5720 that can be added to
the cell cultures directly (Fig. 5). The FRET signal from
the AKAP12 biosensor that increased in response to iso-
proterenol was attenuated sharply by the addition of
KT5720. When KT5720 was added to the medium 5 min
in advance of the isoproterenol, no FRET signal was
recorded in response to the subsequent stimulation by
isoproterenol (results not shown). Thus, chemical inhibi-
tion of PKA in live cells attenuates/blocks the ability of a
beta-adrenergic agonist to stimulate the phosphorylation
of AKAP12 biosensor as evidenced by the FRET signal.
Another test of the veracity of the biosensor to faith-
fully report on the phosphorylation of the AKAP12
fusion molecule by PKA, was to mutate the site of the
PKA phosphorylation in the AKAR2 moiety, designated
AKAR2(T/P)-AKAP12. The impact of this T-to-P substi-
tution mutagenesis in the AKAR2 moiety of the AKAR2-
AKAP12 biosensor on its ability to "biosense" was estab-
lished. The levels of expression of the AKAR2(T/P)-
AKAP12 in A431 cells was similar to that AKAR2-
AKAP12 (results not shown). Treating cells for 10 (or 30
min, not shown) with beta-adrenergic agonist, resulted in
no change in either the CFP or the YFP (FRET) signal in
cells expressing the AKAR2(T/P)-AKAP12 mutant form
of the biosensor (Fig. 6).
Finally, we tested the effects of the HT-31 peptide,
which blocks PKA anchorage to AKAPs, on the ability of
the AKAR2-AKAP12 to "biosense" phosphorylation of
the biosensor AKAP by PKA. The HT-31 peptide was
Figure 4 AKAR2-AKAP12 fusion protein biosensor: FRET signal-
ing in response to beta-adrenergic stimulation. Stably transfected 
A431 clones expressing AKAR-AKAP12 were serum starved over night 
and then stimulated with beta-adrenergic agonist (isoproterenol, 10 
mM) for 30 min. Image and fluorescence density were recorded for CFP 
and YFP in the absence and following the 30 min challenge with iso-
proterenol (+ISO, 30 min). The recordings for CFP and YFP were sam-
pled at 10 sec intervals. The images shown are representative of a large 
array of images collected for this purpose.
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Figure 5 FRET-based "biosensing" by AKAR2-AKAP12 in response 
to beta-adrenergic agonist: effects of addition of PKA inhibitor 
KT5720. Stably transfected A431 clones expressing AKAR-AKAP12 
were serum starved over night and then stimulated with beta-adren-
ergic agonist (isoproterenol, 10 μM) for 30 min. Upper panel, images 
were recorded for CFP and YFP in the absence (0), following the 30 min 
challenge with isoproterenol (+ISO, 30 min), and in the presence of iso-
proterenol for 30 min, then treated with PKA inhibitor KT5720 (+ISO 30 
min, +KT5720) The measurements were made in the perinuclear, cyto-
plasmic area (open red circle) in which robust FRET signals from acti-
vated AKAR2-AKAP12 are observed. Lower panel, the fluorescence 
density measurements were collected from a large array of images col-
lected for this purpose. The fluorescence density of CFP in the same 
area of the cells at basal state (-ISO) is highlighted by a red dashed line.
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delivered in liposomes to A431 cells at 60 min prior to
challenge of the cells with the beta-adrenergic agonist,
isoproterenol. The results demonstrated that through
blocking the interaction between the RII subunit of PKA
and the AKAP, the AKAR2-AKAP12 no longer generates
a FRET signal in response to isoproterenol-stimulated,
PKA-catalyzed phosphorylation (Fig. 7). Next the cells
were treated with the HT-31-prolyl mutant (HT-31p).
This poly prolyl mutation of HT-31 peptide blocks the
ability of the peptide to interfere with PKA RII subunit
binding to AKAPs. Unlike the HT-31 peptide, the prolyl
mutant no longer is able to block the FRET signal gener-
ated in response to stimulation with beta-adrenergic ago-
nist (results not shown). The ability of HT-31 peptide, but
not the HT-31p control peptide, to block AKAR2-
AKAP12 "biosensing" agrees well with much earlier stud-
ies of the ability of the HT-31 peptide to block the RII
subunit-binding domain/AKAP interaction essential to
the dynamic localization of AKAP12 [17]. Likewise,
mutation of the RII subunit-binding site of AKAP12 for
PKA resulted in a mutant that could not rescue the func-
tional responses of AKAP12 in cells made deficient of
endogenous AKAP12 [14].
We extended our analysis of AKAP12 phosphorylation
dynamics by examining the spatial-temporal details of
PKA-catalyzed phosphorylation of the scaffold, using the
AKAR2-AKAP12 biosensor. Earlier it was reported that
AKAP12 is found both localized to the cell membrane as
well as throughout the cytoplasm in large punctate com-
plexes [13-16]. In the unstimulated A431 cells, a modest
AKAR2-AKAP12-derived FRET signal is observed, sug-
gesting that at ambient levels of cyclic AMP and PKA
activation, some cell membrane-associated, phosphory-
lated AKAR2-AKAP12 is present (Fig. 8A). For untreated
A431 cells, the FRET signal images are similar to those of
the eGFP-tagged AKAP12 [15]. AKAP5 and AKAP12
both display three PCDs that dictate increased proximity
to the cell membrane in the absence of AKAP phosphory-
lation [5,6,16].
Figure 6 FRET-based "biosensing" by AKAR2(T/P) mutant-
AKAP12 in response to beta-adrenergic agonist. Stably transfected 
A431 clones expressing AKAR2(T/P) mutant of AKAP12 (lacking the 
phosphorylation site for PKA in the substrate domain of the AKAR2 
moiety) were serum starved over night and then untreated (-ISO) or 
treated with beta-adrenergic agonist (isoproterenol, 10 μM for 10 min 
(+ ISO 10 min). Upper panel, images and fluorescent densities recorded 
for CFP and YFP are displayed. The measurements were made in the 
perinuclear, cytoplasmic area (open red circle), an area in which robust 
FRET signals from activated AKAR2-AKAP12 are observed. Lower panel, 
the fluorescence density measurements were analyzed from a large ar-
ray of images collected for this purpose. The fluorescence density of 
CFP in the same area of the cells at basal state (-ISO) is highlighted by 
a red dashed line.
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Figure 7 FRET-based "biosensing" by AKAR2-AKAP12 in response 
to beta-adrenergic agonist: effects of HT-31 peptide interference 
of AKAP/RII subunit-binding. Stably transfected A431 clones ex-
pressing AKAR-AKAP12 were serum starved over night, pre-treated 
with liposomes loaded with the HT-31 peptide (50 μM loading), and 
then stimulated with beta-adrenergic agonist (isoproterenol, 10 μM) 
for 10 min. Upper panel, images were recorded for CFP and YFP from 
the HT-31 peptide-treated cells that were then incubated either with-
out isoproterenol (-ISO), or with isoproterenol (+ISO, 10 μM) for 10 min. 
The measurements were made in the perinuclear, cytoplasmic area 
(open red circle), an area in which robust FRET signals from activated 
AKAR2-AKAP12 are observed. Lower panel, the fluorescence density 
measurements were collected from a large array of images collected 
for this purpose. The fluorescence density of CFP in the control cells (-
HT31) at basal state (-ISO) is highlighted by a red dashed line.
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Stimulation of A431 cells with beta-adrenergic agonist
provokes a 3-5 fold increase in the amount of AKAP12
localized to the cell membrane [16-18]. We analyzed the
FRET signal from A431 cells expressing AKAR2-AKAP12
biosensor at various times following stimulation of the
cells with beta-adrenergic agonist (Fig. 8A). Utilizing sin-
gle cell recordings, FRET signals were scanned for two
specific regions: a region which is largely perinuclear,
cytoplasmic in character (open yellow circle) and a region
that is largely cell membrane (open red, rectilinear box).
Cells were treated with beta-adrenergic agonist and the
FRET signal measured at various intervals over the next
30 min. Within the first 5 min of treatment with isoprot-
erenol, FRET signals from the AKAP12 biosensor
scanned at the cell membrane increased (Fig. 8B, left-
handed panel). These data suggest that PKA-catalyzed
phosphorylation, which is necessary for the receptor
resensitization and receptor recycling functions of
AKAP12, is readily "biosensed" at the cell membrane and
reflects PKA-catalyzed phosphorylation of the scaffold
which accumulates at the cell membrane during activa-
tion [13-15]. Over time, following stimulation by beta-
adrenergic agonist, a steady-state appears to be reached
in which the amount of AKAP12 phosphorylated at cell
membrane remains rather constant, even though bio-
chemical studies clearly demonstrate that it is accumulat-
ing first at the cell membrane and later in the cytoplasm
where the mobile scaffold is associated with the internal-
ized GPCR [4,13-15].
The FRET signal from the AKAR2-AKAP12 sampled
from the perinuclear, cytoplasmic region of the cells (see
open yellow circles) displays a forward, progressive
increase to 30 min post-stimulation, the last time sam-
pled (Fig. 8A and 8B, right-handed panel). The magnitude
of the FRET signal over the 30 min period of stimulation
of GPCR appears to reflect the progressive accumulation
of AKAP12 scaffold at perinuclear, cytoplasmic regions
noted earlier [13-15]. The scaffold, internalized and
migrating in association with the internalized GPCR,
clearly displays a FRET signal that is pronounced and
progressively increasing over the 30 min of observation
following treatment of the cells with isoproterenol. In the
absence of AKAP12 phosphorylation (due to mutagenesis
of the PKA RII subunit-binding site), desensitized GPCR
have been shown to undergo internalization, but neither
resensitization nor recycling [14]. During the interval of
stimulation by beta-adrenergic agonist, AKAP12
becomes phosphorylated in response to activation of
PKA and accumulates in the cytoplasm, where it cata-
lyzes a necessary resensitization and recycling of desensi-
tized beta2-adrenergic receptors.
Conclusion
The current data shed important new light on the
dynamics of AKAP12 in response to a challenge of cells
with a beta-adrenergic agonist. It is the first time that a
biosensor has been fused with a scaffold molecule in an
attempt to yield a biosensor fusion protein designed to
detect the phosphorylation and activation of a targeted
PKA substrate, in this case AKAP12. The AKAR2-
AKAP12 displays full ability to function in resensitization
and recycling of GPCRs to the cell membrane, once they
have undergone activation/desensitization. Although
some details of the AKAP biology were revealed by static
determinations and largely biochemical means [1-4], the
ability to "biosense" only the AKAP12 molecules that
undergo PKA-catalyzed phosphorylation and activation
(with respect to function) in a time-space continuum was
a worthwhile goal to seek. The biosensor fusion protein
Figure 8 FRET signaling from AKAR2-AKAP12 fusion protein "bio-
senses" dynamics of phosphorylated, activated AKAP. Panel A, 
A431 cells were stably transfected with AKAR2-AKAP12. Cells were put 
in serum starvation for 12 hrs before the recording. Images were re-
corded for CFP and YFP in absence and presence of isoproterenol (10 
μM) and sampled from time = "0" min until time = 30 min. The sam-
pling of the FRET was confined to two cellular locales: the cell mem-
brane (open red rectangles) and the perinuclear, cytoplasmic regions 
(open yellow circles). The images shown are representative of a large 
array of images collected for this purpose. Panel B, the fluorescence 
densities in cell membrane and perinuclear areas were recorded for 
CFP and for YFP in absence and presence of beta-adrenergic agonist. 
The data sets are from many samplings, performed on individual cells, 
and displayed as a representative fluorescence density scan over time.
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AKAR2-AKAP12 yielded a FRET signal upon stimulation
of the cells with isoproterenol. The magnitude of the
FRET signal suggests that only some of the AKAP12 at or
in the vicinity of the cell membrane undergoes initial
PKA-catalyzed phosphorylation. Stimulation of the
GPCR results in a 3-5 fold increase in the cell membrane-
associated AKAP12, some being physically-associated
with the GPCR and some phosphorylated by PKA. The
magnitude of the FRET signal would be most consistent
with PKA-catalyzed phosphorylation of AKAP12 fol-
l o w e d  b y  ev e n t u a l  r ed i s t r i b u t i o n  a w a y  f r o m  t h e  m e m -
b r a n e ;  t h i s  c o n c l u s i o n  i s  buttressed by earlier
immunohistochemical and biochemical analyses. We are
able here to demonstrate the space-time localization of
the phosphorylated, activated AKAPs (i.e., still phospho-
rylated). If the PKA-catalyzed phosphorylation occurred
prior to beta-adrenergic agonist-induced accumulation of
the AKAP at the membrane (which peaks within 5-10
min), then the increase in FRET would have been
expected to be more robust.
The increase in the perinuclear, cytoplasmic FRET sig-
nal reflects the agonist-induced internalization of GPCR/
phospho-AKAP12 complex, revealing for the first time
those AKAR2-AKAP12 phosphorylated by PKA. The
accumulation of the PKA-phosphorylated and activated
form of the AKAP12 away from the cell membrane
appears to be associated with the ability of AKAP12 to
rescue desensitized GPCRs through a process of resensi-
tization and eventual recycling to the cell membrane. The
AKAR2-AKAP12 fusion protein is able to "biosense" the
PKA-catalyzed phosphorylation of the scaffold and
report on its cellular locale. The phosphorylation by PKA
is necessary for the scaffold function in receptor resensi-
tization and recycling, a cardinal process in the rescue of
desensitized GPCRs, exemplified herein by study of
beta2-adrenergic receptors. Clearly, the availability of an
AKAP-biosensor that can report back on the phosphory-
lation status of AKAP with respect to PKA (and by suit-
able engineering, other interesting protein kinases, like
Src [18]) permits the interrogation of the spatial-tempo-
ral sequence of events in which phosphorylated AKAP12
participates in the resensitization and recycling of
GPCRs. This biosensor fusion protein strategy of use in
study of AKAP biology will likely provide powerful new
tools for the analysis of the space-time continuum for
other dynamic, multivalent scaffolds such as the Dishev-
elleds [19].
Methods
Cell culture
Human epidermoid carcinoma cells (A431) were main-
tained in Dulbecco's modified Eagle's medium supple-
mented with 10% fetal bovine serum (HyClone, Logan,
UT), penicillin (60 μg/ml), and streptomycin (100 μg/ml)
and grown in a humidified atmosphere of 5% CO2 and
95% air at 37°C. A431 cells were transfected with AKAR2
pcDNA3.1 or AKAR2-AKAP12 pcDNA3 hygro  using
Lipofectinamine Plus™ and Plus (Invitrogen) according to
the manufacturer's protocol, and viable clones were
selected in 400 μg/ml of the neomycin analogue G418 or
hygromycin.
Construction of AKAR2-AKAP12
AKAR2 was amplified by using PCR with primers con-
taining Nhe I and Kpn1 at N or C terminal. AKAP2 was
inserted in PcDNA3 hygro  between Nhe I and Kpn 1.
AKAP12' (1-2180) was amplified by using PCR with
primers containing Kpn1 and BamH1 at H2N-terminus
or -COOH-terminus. The PCR product then was sub-
cloned in the AKAR2-pcDNA3 hygro. AKAP12" (2181-
5346) was amplified by using PCR with primers contain-
ing BamH1 and Not1 at H2N-terminus or -COOH-termi-
nus. This PCR product then was subcloned into the
pcDNA3-AKAR2-AKAP'construct to form a complete
AKAR2-AKAP12 pcDNA3 hygro construct. Sequences of
all primers used are available from the authors upon
request. Threonine-to-Proline substitution mutant of
AKAR2-AKAP12 at PKA phosphorylation site in AKAR2
was engineered by standard protocol for PCR-mediated
mutagenesis. All the PCR was performed using Pfu poly-
merase (Stratagene). The integrity of the amplified
sequence was confirmed by DNA sequencing.
Immunoblotting
A431 cell extracts were probed for AKAP5 or AKAP12
expression by immunoblotting. Cells were stimulated
with 10 μM isoproterenol for different time intervals.
Cells were harvested and lysed in a lysis buffer (1% Triton
X-100, 0.5% Nonidet-40, 10 mM dithiothreitol, 5 μg/ml
aprotinin, 5 μg/ml leupeptin, 100 μg/ml bacitracin, 100
μg/ml benzamidine, 2 mM sodium orthovanadate, 150
mM NaCl, 5 mM EDTA, 50 mM NaF, 40 mM sodium
pyrophosphate, 50 mM KH2PO4, 10 mM sodium molyb-
date, and 20 mM Tris-HCl, pH 7.4) at 4°C for 20 min
Desensitization and resensitization of β2AR
Two days prior to the analysis of agonist-induced desensi-
tization, the A431 cells were seeded in 96-well microtiter
plates at a density of 25,000-50,000 cells/well. Routinely
cells were serum-starved overnight, prior to analysis.
Desensitization was accomplished by pretreating the cells
with the beta-adrenergic agonist isoproterenol (10 μM)
for 30 min. Under these conditions, subsequent beta-
adrenergic stimulation of cyclic AMP accumulation is
severely blunted and the number of cell-surface receptors
declines precipitously as the receptors are sequestered
and internalized. Details of the desensitization protocol
are described elsewhere [14-17].Tao et al. Journal of Molecular Signaling 2010, 5:3
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Knockdown of AKAP12 with antisense morpholinos
Antisense morpholino oligonucleotides (morpholinos)
were designed, synthesized, and purified to cell culture
grade (Gene Tools, LLC). The morpholinos and protocol
for knockdown (KD) of endogenous AKAP12 expression
were optimized and reported earlier [18]. The extent of
the suppression of gravin expression by antisense mor-
pholinos in these studies was >85%. The antisense mor-
pholinos were designed to target the 5'-untranslated
region of the mRNA for native AKAP12 and do not rec-
ognize AKAP12 mRNA transcribed from the expression
vector (pcDNA3). Prior to their addition to A431 cell cul-
tures, morpholinos were mixed in a ratio of 1:1 (w/w)
with EPEI special delivery solution (Gene Tools, LLC).
Cells were treated with the anti-AKAP12 morpholinos (5
μg/ml) for 3 days. Whole cell lysates of the morpholino-
treated cells were subjected to SDS-PAGE and the
resolved proteins were blotted and stained with anti-
gravin antibody. Under standard conditions, morpholinos
antisense for AKAP12 suppressed the cellular level of the
AKAP by more than 90% [13,18]. An additional treatment
with morpholinos antisense to AKAP12 was performed
prior to transient transfection of the cells with either
wild-type (WT) or mutant forms of AKAP12. The mor-
pholinos are designed to suppress the expression of
endogenous AKAP12 at a 5'-untranslated region, not
interfering with the AKAP12 (or AKAR2-AKAP12)
expressed through use of mammalian expression vector,
pcDNA3. Following this protocol, cells were analyzed for
beta-adrenergic agonist-induced (i.e. Iso, 10 μM) desensi-
tization, as well as the recovery (i.e. resensitization and
recycling of beta2-adrenergic receptors) after washout of
agonist.
Confocal fluorescence and fluorescence emission
Measurements were performed at 37°C on Zeiss LSM 510
scanning laser confocal microscope with 40×/1.3 numeri-
cal aperture Plan Apochromatic oil immersion objective
lens with three laser lines (targeting specifically CFP, YFP
(citrine variant), and DAPI). The fluorescence was
detected by 3 high efficiency photomultipliers (CFP, 473-
495 nm; YFP and FRET, 527-591 nm; DAPI, 435-485).
Cells were scanned at 400 lines/s and with four times
averaging. Images (512 × 512 pixels) were optimized and
overlay images (YFP/CFP or YFP/CFP/DAPI) created
with LSM image browser. A time series consisting of
images that were captured every 5 min was obtained for
each cell. Cells were stimulated with beta-adrenergic ago-
nist (isoproterenol) in either the presence or the absence
of indicated chemical inhibitors of enzymes, as described
above.
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